Safety of dapagliflozin in Asian patients with type 2 diabetes mellitus:a Meta-analysis
Zhenwei Fang,Jia Shi,Xiujin Shi,Huilin Tang,Yang Lin
DOI: https://doi.org/10.3760/cma.j.issn.1008-5734.2017.03.009
2018-01-01
Abstract:Objective To evaluate the safety of dapagliflozin in Asian patients with type 2 diabetes mellitus (T2DM ). Methods Randomized controlled trials (RCTs ) which evaluated the safety of dapagliflozin in Asian patients with T2DM from related databases and clinical trial registries from establishment to July 27,2017 were searched. The patients who treated with dapagliflozin enrolled the dapagliflozin group. The patients who received placebo or other hypoglycemic agents enrolled the control group. The primary safety endpoints included cardiovascular safety,hypoglycemia,genital tract infection and urinary tract infection. The secondary safety endpoints included tumor,pyelonephritis,renal failure, fracture,amputation,etc. Meta-analysis was conducted using RevMan 5.3 and Stata 12.1 software. Risk ratio (RR)and 95% confidence intervals (CI)were calculated for dichotomous outcomes. Mean difference (MD)and 95% CI were calculated for continuous outcomes. Results A total of 9 RCTs involving 1 857 Asian T2DM patients enrolled the study. Of 1 857 patients,1 180 patients were in the dapagliflozin group and 677 patients were in the control group [the placebo group:619 patients;the dipeptidyl peptidase-4 (DPP4 ) inhibitor group:58 patients ]. The results of Meta-analysis showed that the differences of incidences of major adverse cardiovascular events (MACE ),non-fatal myocardial infarction,non-fatal stroke,hypoglycemia,and urinary tract infection between the dapagliflozin group and the placebo group were all no statistical significance[0.58% (4/684)vs. 0.99% (4/406),RR＝0.59,95% CI:0.17-2.02, P＝0.40],[0.20% (1/510)vs. 0.63% (2/319),RR ＝0.43,95% CI:0.08-2.30,P ＝0.33], [0.52% (3/574)vs. 0.57% (2/352),RR＝0.76,95% CI:0.18-3.24,P＝0.71],[5.79% (65/1 122)vs. 8.08% (50/619),RR＝0.92,95% CI:0.67-1.28,P＝0.64],and [3.48% (39/1 122) vs. 3.39% (21/619),RR＝1.03,95% CI:0.61-1.73,P＝0.91],respectively. The incidence of genital tract infection in the dapagliflozin group was higher than that in the placebo group,but the difference was statistically significant [2.08% (23/1 105)vs. 0.33% (2/611),RR＝3.42,95% CI:1.21-9.70,P＝0.02 ]. The result of subgroup analysis showed that the incidence of genital tract infection in the dapagliflozin 10 mg group was higher than that in the placebo group,the difference was statistically significant [2.30% (13/564)vs. 0.36% (2/551),RR＝4.56,95CI:1.32-15.78,P＝0.02]. There were no significant correlations of other major endpoint events between the dapagliflozin groups in different dosage and the placebo group. The level of serum uric acid,compared with the baseline in the dapagliflozin group,decreased more than that in the placebo group,the difference was statistically significant (MD ＝－15.47 μmol/L,95% CI:－30.35-－0.60,P ＝0.04). There were no statistical significances of the incidences of tumor,renal adverse events,fracture,and amputation between the dapagliflozin group and the placebo group (all P＞0.05). The level of estimated glomerular filtration rate,compared with the baseline in the dapagliflozin group,decreased similar to that in the DPP4 inhibitor group,the difference was not statistically significant [MD ＝ 1. 70 ml/(min1. 73 m2),95% CI:－ 7. 79-11. 19,P ＝ 0. 73 ]. Conclusions Dapagliflozin is relatively safe in the treatment of Asian patients with type 2 diabetes. It should be vigilant for the probability of genital tract infection induced by dapagliflozin in the clinical practice.